Print Page     Close Window     

SEC Filings

6-K
AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document
 
 

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 16 Crenezumab Unique competitive position - Phase 2 - encouraging efficacy with favorable safety Efficacy ▪ 24 % and 35% reduction in primary endpoint ADAS - cog in ABBY mild patient subsets (MMSE 20 - 26 (1) and 22 - 26 (2 ) ) ▪ Replicated in BLAZE with 52% reduction in ADAS - cog in mild patient subset (MMSE 20 - 26) ▪ Consistent effects over time also seen in other endpoints (DSST, MMSE) ▪ Positive trend in functional endpoint, CDR - SB (20 % (3) to 45 % (4) reduction in ABBY, 41.5% reduction in BLAZE (5) ) ▪ Significant increase in CSF Abeta1 - 42 confirms target engagement ▪ Analysis of PET data with white matter reference suggest reduction of amyloid accumulation Safety ▪ Only one case of vasogenic edema /ARIA - E and AE profile ▪ Open label safety extension study resulted in favorable safety without any cases of ARIA - E Data of high dose IV cohort in ABBY and BLAZE showed treatment effect in the mild AD patient subset with favorable safety Crenezumab showed consistent results over time, over several endpoints and different studies ADAS - cog : (1) MMSE 20 - 26: pre - specified analyis of data, (2) MMSE 22 - 26 non pre - specified exploratory analysis of data CDR - SB: Exploratory analysis in patients with mild symptoms, treatment with high - dose IV crenezumab , results not statistically significant: (3) MMSE 22 - 26, (4) MMSE 24 - 26 (5) Post - hoc analysis in patients with mild AD (MMSE 20 - 26), treatment with high - dose IV crenezumab , p=0.44. AE = Adverse Events, CSF = cerebrospinal fluid

 

© AC Immune 2015